Jaguar Health, Inc. (JAGX) stock
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.39−0.03 (-7.14%)
Close on Nov 16, 2026Market cap $2.02MP/E –Yield –
Jaguar Health r&d expenses
Research and development expenses are spending on new products and technology.
Jaguar Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $25.24M, up 62.1% year over year. For fiscal 2025 it was $24.97M, up 50.9% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is $24.97M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.97M | +50.9% |
| FY2024 | Dec 31, 2024 | $16.54M | -11.0% |
| FY2023 | Dec 31, 2023 | $18.60M | +5.4% |
| FY2022 | Dec 31, 2022 | $17.65M | +17.0% |
| FY2021 | Dec 31, 2021 | $15.08M | +135.1% |
| FY2020 | Dec 31, 2020 | $6.41M | +10.2% |
| FY2019 | Dec 31, 2019 | $5.82M | +12.9% |
| FY2018 | Dec 31, 2018 | $5.15M | +20.7% |
| FY2017 | Dec 31, 2017 | $4.27M | -40.8% |
| FY2016 | Dec 31, 2016 | $7.21M | +11.3% |
| FY2015 | Dec 31, 2015 | $6.48M | +53.4% |
| FY2014 | Dec 31, 2014 | $4.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.34M | +2.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.93M | +5.3% |
| Q4 FY2025 | Dec 31, 2025 | $14.31M | +215.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.66M | -9.5% |
| Q2 FY2025 | Jun 30, 2025 | $3.27M | -10.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.73M | -13.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.53M | +30.9% |
| Q3 FY2024 | Sep 30, 2024 | $4.04M | -33.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.65M | -14.6% |
| Q1 FY2024 | Mar 31, 2024 | $4.31M | -9.7% |
| Q4 FY2023 | Dec 31, 2023 | $3.46M | -19.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.08M | +2.4% |
| Q2 FY2023 | Jun 30, 2023 | $4.28M | +74.5% |
| Q1 FY2023 | Mar 31, 2023 | $4.78M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $4.31M | -21.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.94M | +79.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.45M | -36.7% |
| Q1 FY2022 | Mar 31, 2022 | $4.95M | +104.8% |
| Q4 FY2021 | Dec 31, 2021 | $5.48M | +187.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.31M | +117.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.87M | +175.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.41M | +52.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.90M | +36.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.52M | +16.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.41M | -17.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.58M | +11.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.39M | +6.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.31M | -11.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.70M | +37.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.42M | +66.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.31M | +41.4% |
| Q3 FY2018 | Sep 30, 2018 | $1.48M | +18.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.24M | -19.5% |
| Q3 FY2017 | Sep 30, 2017 | $851.61K | -56.7% |
| Q2 FY2017 | Jun 30, 2017 | $926.79K | -52.6% |
| Q1 FY2017 | Mar 31, 2017 | $1.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.53M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.97M | – |
| Q2 FY2016 | Jun 30, 2016 | $1.95M | – |
See a number that looks wrong?